Related Experiment Videos
Infliximab use in Crohn's disease
Meenakshi Bewtra1, Gary R Lichtenstein
1University of Pennsylvania Health System, 100 Centrex, IMR, 3400 Spruce Street, Philadelphia, PA 19104, USA. meenakshi.bewtra@uphs.upenn.edu
Expert Opinion on Biological Therapy
|June 7, 2005
Summary
Infliximab effectively treats Crohn's disease, a severe gastrointestinal inflammatory condition. This review covers its efficacy, uses, safety, and future in managing Crohn's disease.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Crohn's disease is a chronic, severe gastrointestinal inflammatory condition.
- It often requires extensive medical and surgical interventions.
- Tumor necrosis factor (TNF) is a key inflammatory cytokine in Crohn's disease pathogenesis.
Purpose of the Study:
- To review the clinical efficacy of infliximab in treating Crohn's disease.
- To outline the indications and safety profile of infliximab therapy.
- To discuss the future prospects of infliximab for Crohn's disease management.
Main Methods:
- Review of numerous studies on infliximab treatment for Crohn's disease.
- Analysis of clinical and endoscopic outcomes.
- Evaluation of safety data and patient profiles.
Main Results:
- Infliximab treatment demonstrates significant clinical improvement in Crohn's disease.
- Endoscopic healing of luminal and fistulising Crohn's disease is observed.
- Positive outcomes reported across multiple studies.
Conclusions:
- Infliximab is an effective therapeutic option for Crohn's disease.
- The review provides comprehensive insights into its use, safety, and future.
- Further research may refine infliximab's role in managing this chronic condition.